Table 3.

Across 1 year, mycophenolic acid (MPA) plasma concentration and biomarkers in peripheral blood mononuclear cells (PBMC) in patients requiring reduction of the mycophenolate mofetil dose (median, quartiles)

		Patients with dose reduction (n = 6)	Patients without dose reduction (n = 18)	P*
Trough plasma MPA (mg L−1)		3.22 (2.11–4.38)	1.79 (1.50–2.79)	.036
Stimulated PBMC	IMPDH capacity (pmol 10−6 cells min−1)	26.0 (11.2–43.5)	65.3 (4.2–96.0)	.042
	Guanine (nmol 10−6 cells)	0.91 (0.62–1.37)	2.18 (1.12–2.65)	.042
	Adenine (nmol 10−6 cells)	2.27 (1.34–3.27)	4.50 (2.40–5.15)	.042
Nonstimulated PBMC	IMPDH capacity (pmol 10−6 cells min−1)	2.96 (2.34–3.12)	4.50 (3.30–6.16)	.025
	Guanine (nmol 10−6 cells)	0.78 (0.54–0.85)	0.85 (0.70–1.20)	.48
	Adenine (nmol 10−6 cells)	1.45 (1.33–1.49)	2.08 (1.52–2.34)	.042

Median (quartiles) of average predose measurements at 6–9 days, 5–7 weeks and 1 year. Omitting samples taken at time points when the mycophenolate mofetil dose was reduced. *Differences in cross‐year averages between patients with and without dose reduction tested using Mann–Whitney U test

IMPDH, inosine monophosphate dehydrogenase